KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Net Cash Flow (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Net Cash Flow for 13 consecutive years, with $94.8 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 68.46% to $94.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.0 million through Dec 2025, up 1414.7% year-over-year, with the annual reading at $56.0 million for FY2025, 1414.7% up from the prior year.
  • Net Cash Flow for Q4 2025 was $94.8 million at Xenon Pharmaceuticals, up from -$30.9 million in the prior quarter.
  • The five-year high for Net Cash Flow was $254.3 million in Q2 2022, with the low at -$263.8 million in Q3 2022.
  • Average Net Cash Flow over 5 years is $6.4 million, with a median of $5.6 million recorded in 2021.
  • Peak annual rise in Net Cash Flow hit 5427.59% in 2022, while the deepest fall reached 5053.06% in 2022.
  • Over 5 years, Net Cash Flow stood at $87.8 million in 2021, then plummeted by 153.59% to -$47.1 million in 2022, then surged by 203.74% to $48.8 million in 2023, then rose by 15.21% to $56.2 million in 2024, then soared by 68.46% to $94.8 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $94.8 million, -$30.9 million, and $18.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.